The Lancet Oncology最新文献

英文中文

Projected global rise in breast cancer incidence and mortality by 2050

The Lancet Oncology

Pub Date : 2025-03-06 DOI: 10.1016/s1470-2045(25)00136-6

Sharmila Devi

No Abstract

引用次数: 0

Chemical industry lobbyists will run chemical safety oversight at US EPA

The Lancet Oncology

Pub Date : 2025-03-06 DOI: 10.1016/s1470-2045(25)00135-4

Bryant Furlow

No Abstract

引用次数: 0

Children and young people with cancer affected by disability benefit delays

The Lancet Oncology

Pub Date : 2025-03-06 DOI: 10.1016/s1470-2045(25)00137-8

Elizabeth Gourd

No Abstract

引用次数: 0

Destroy or delay: hormonal therapy in oligometastatic prostate cancer 摧毁还是拖延：寡转移前列腺癌的激素疗法

The Lancet Oncology

Pub Date : 2025-03-03 DOI: 10.1016/s1470-2045(25)00016-6

Amar U Kishan, Luca F Valle

No Abstract

引用次数: 0

Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer

The Lancet Oncology

Pub Date : 2025-03-03 DOI: 10.1016/s1470-2045(25)00028-2

Anthony Gonçalves, Alexandre de Nonneville

No Abstract

引用次数: 0

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial

The Lancet Oncology

Pub Date : 2025-03-03 DOI: 10.1016/s1470-2045(24)00730-7

Giulia Marvaso, Giulia Corrao, Mattia Zaffaroni, Maria Giulia Vincini, Chiara Lorubbio, Sara Gandini, Cristiana Fodor, Sofia Netti, Dario Zerini, Stefano Luzzago, Francesco Alessandro Mistretta, Konstantinos Venetis, Giulia Cursano, Tiziana Burla, Ketti Mazzocco, Federica Cattani, Giuseppe Petralia, Nicola Fusco, Gabriella Pravettoni, Gennaro Musi, Barbara Alicja Jereczek-Fossa

<h3>Background</h3>Metastasis-directed therapy by stereotactic body radiotherapy (SBRT) has been shown to improve clinical outcomes in the oligometastatic prostate cancer setting. We aimed to investigate whether short-course androgen deprivation therapy (ADT) and SBRT at all oligometastatic sites versus SBRT alone improves clinical progression-free survival in men with metachronous oligorecurrent hormone-sensitive prostate cancer.<h3>Methods</h3>The RADIOSA study was a single-centre, randomised, open-label, controlled phase 2 trial done in the European Institute of Oncology, IRCCS, Milan, Italy. Key eligibility criteria were histologically proven initial diagnosis of adenocarcinoma of the prostate, biochemical progression after radical local prostate treatment, nodal relapse in the pelvis, extra-regional nodal relapse, bone metastases at next-generation imaging with a maximum of three lesions, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, and age 18 years or older. Participants were stratified according to prostate-specific membrane antigen doubling time (≤3 <em>vs</em> >3 months), metastases localisation (node <em>vs</em> bone), and diagnostic imaging (positron emission tomography <em>vs</em> MRI) and were randomly assigned (1:1) using a computer-generated random number to SBRT alone or SBRT in combination with 6 months of ADT. For SBRT treatment, a schedule of 30 Gy in three fractions every other day (with the equivalent dose in 2 Gy fractions being 98·6 Gy, considering α/β ratio of 1·5 Gy and biologically effective dose of >100 Gy), or equivalent regimens depending on disease site location, was administered. Patients in the SBRT with ADT group received 6 months of ADT with a luteinising hormone-releasing hormone analogue within 1 week before the start of SBRT. The allocated treatment was not masked. The primary outcome measure was clinical progression-free survival. All analyses followed a modified intention-to-treat principle, consisting of all patients assigned to a treatment group who had available data. The trial is registered at ClinicalTrials.gov, NCT02680587, and is complete.<h3>Findings</h3>Between Aug 1, 2019, and April 30, 2023, 218 patients were assessed for eligibility, 113 were excluded, and 105 were enrolled and randomly assigned to an intervention (52 to SBRT only and 53 to SBRT with ADT). Three patients were lost to follow-up and 51 patients in each group were assessed for the primary outcome. The median age at study enrolment was 70 years (IQR 65–75); data on race and ethnicity were not collected. With a median follow-up of 31 months (IQR 16–36) for both groups, the median clinical progression-free survival was 15·1 months (95% CI 12·4–22·8) for the SBRT group versus 32·2 months (22·4–not reached) for the SBRT with ADT group (hazard ratio 0·43 [95% CI 0·26–0·72], p=0·0010]). One gastrointestinal grade 1 adverse event (SBRT group) and one genitourinary grade 3 adverse event (left ureter stenosis, SBRT

{"title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","authors":"Giulia Marvaso, Giulia Corrao, Mattia Zaffaroni, Maria Giulia Vincini, Chiara Lorubbio, Sara Gandini, Cristiana Fodor, Sofia Netti, Dario Zerini, Stefano Luzzago, Francesco Alessandro Mistretta, Konstantinos Venetis, Giulia Cursano, Tiziana Burla, Ketti Mazzocco, Federica Cattani, Giuseppe Petralia, Nicola Fusco, Gabriella Pravettoni, Gennaro Musi, Barbara Alicja Jereczek-Fossa","doi":"10.1016/s1470-2045(24)00730-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00730-7","url":null,"abstract":"<h3>Background</h3>Metastasis-directed therapy by stereotactic body radiotherapy (SBRT) has been shown to improve clinical outcomes in the oligometastatic prostate cancer setting. We aimed to investigate whether short-course androgen deprivation therapy (ADT) and SBRT at all oligometastatic sites versus SBRT alone improves clinical progression-free survival in men with metachronous oligorecurrent hormone-sensitive prostate cancer.<h3>Methods</h3>The RADIOSA study was a single-centre, randomised, open-label, controlled phase 2 trial done in the European Institute of Oncology, IRCCS, Milan, Italy. Key eligibility criteria were histologically proven initial diagnosis of adenocarcinoma of the prostate, biochemical progression after radical local prostate treatment, nodal relapse in the pelvis, extra-regional nodal relapse, bone metastases at next-generation imaging with a maximum of three lesions, Eastern Cooperative Oncology Group (ECOG) performance status 0–1, and age 18 years or older. Participants were stratified according to prostate-specific membrane antigen doubling time (≤3 <em>vs</em> >3 months), metastases localisation (node <em>vs</em> bone), and diagnostic imaging (positron emission tomography <em>vs</em> MRI) and were randomly assigned (1:1) using a computer-generated random number to SBRT alone or SBRT in combination with 6 months of ADT. For SBRT treatment, a schedule of 30 Gy in three fractions every other day (with the equivalent dose in 2 Gy fractions being 98·6 Gy, considering α/β ratio of 1·5 Gy and biologically effective dose of >100 Gy), or equivalent regimens depending on disease site location, was administered. Patients in the SBRT with ADT group received 6 months of ADT with a luteinising hormone-releasing hormone analogue within 1 week before the start of SBRT. The allocated treatment was not masked. The primary outcome measure was clinical progression-free survival. All analyses followed a modified intention-to-treat principle, consisting of all patients assigned to a treatment group who had available data. The trial is registered at ClinicalTrials.gov, NCT02680587, and is complete.<h3>Findings</h3>Between Aug 1, 2019, and April 30, 2023, 218 patients were assessed for eligibility, 113 were excluded, and 105 were enrolled and randomly assigned to an intervention (52 to SBRT only and 53 to SBRT with ADT). Three patients were lost to follow-up and 51 patients in each group were assessed for the primary outcome. The median age at study enrolment was 70 years (IQR 65–75); data on race and ethnicity were not collected. With a median follow-up of 31 months (IQR 16–36) for both groups, the median clinical progression-free survival was 15·1 months (95% CI 12·4–22·8) for the SBRT group versus 32·2 months (22·4–not reached) for the SBRT with ADT group (hazard ratio 0·43 [95% CI 0·26–0·72], p=0·0010]). One gastrointestinal grade 1 adverse event (SBRT group) and one genitourinary grade 3 adverse event (left ureter stenosis, SBRT ","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personalised cancer vaccines and new regulatory struggles

The Lancet Oncology

Pub Date : 2025-03-03 DOI: 10.1016/s1470-2045(25)00096-8

No Abstract

引用次数: 0

AI model using clinical images for genomic prediction and tailored treatment in patients with cancer

The Lancet Oncology

Pub Date : 2025-03-03 DOI: 10.1016/s1470-2045(25)00008-7

Song-Bin Guo, Xiu-Yu Cai, Yuan Meng, Wei-Juan Huang, Xiao-Peng Tian

No Abstract

引用次数: 0

Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial

The Lancet Oncology

Pub Date : 2025-03-03 DOI: 10.1016/s1470-2045(25)00001-4

Takehito Shukuya, Tetsuhiko Asao, Yasushi Goto, Tomoyasu Mimori, Koichi Takayama, Kyoichi Kaira, Hiroshi Tanaka, Ryo Ko, Yoshihiro Amano, Motoko Tachihara, Takuji Suzuki, Junko Tanizaki, Shunichi Sugawara, Yoshitaka Zenke, Yukina Shirai, Takuo Hayashi, Keita Mori, Kazuhisa Takahashi

Background

Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains a standard treatment for chemotherapy-naive advanced or recurrent thymic carcinoma. We evaluated the activity and safety of atezolizumab combined with chemotherapy.

Methods

In this multicentre, single-arm, phase 2 trial in 15 hospitals in Japan, patients with metastatic or recurrent thymic carcinoma were treated with atezolizumab plus carboplatin and paclitaxel. Eligible patients were aged 20 years or older with histologically confirmed Masaoka stage III, IVA, or IVB thymic carcinoma not amenable for definitive treatment or recurrent thymic carcinoma after definitive treatment; and no previous history of systemic drug therapy for thymic carcinoma. The data of sex and race were defined via self-report. Patients received atezolizumab 1200 mg, carboplatin area under the curve 6 mg/mL per min, and paclitaxel 200 mg/m² intravenously every 3 weeks for up to six cycles, followed by atezolizumab 1200 mg intravenously every 3 weeks for up to 2 years until progression or unacceptable toxicity. The primary endpoint was objective response rate, based on an independent central review. The primary endpoint and safety were assessed in the per-protocol set. This trial was registered at Japan Registry of Clinical Trials, jRCT2031220144, and is closed to enrolment.

Findings

Between June 14, 2022, and July 6, 2023, 48 patients were enrolled and included in the efficacy and safety analyses. Median follow-up was 15·3 months (IQR 13·8–16·6). 29 (60%) patients were male and 19 (40%) of 48 patients were female. Median age of patients was 67·5 years (IQR 56·5–72·5). All patients were Asian. The objective response rate was 56% (95% CI 41–71; Fisher's exact test p<0·0001); 27 (56%) of 48 participants had a partial response. The most common adverse reactions of grade 3 or worse were neutropenia (27 [56%] of 48 patients), leukopenia (16 [33%]), febrile neutropenia (11 [23%]), and maculopapular rash (six [13%]). There were no treatment-related deaths and eight deaths overall.

Interpretation

In previously untreated advanced thymic carcinoma, the addition of atezolizumab to carboplatin and paclitaxel conferred clinically meaningful antitumour activity with a manageable safety profile. Thus, atezolizumab plus carboplatin and paclitaxel might become a viable treatment option for previously untreated advanced or recurrent thymic carcinoma.

Funding

Chugai Pharmaceutical.

Translations

For the Japanese translation of the abstract see Supplementary Materials section.

{"title":"Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial","authors":"Takehito Shukuya, Tetsuhiko Asao, Yasushi Goto, Tomoyasu Mimori, Koichi Takayama, Kyoichi Kaira, Hiroshi Tanaka, Ryo Ko, Yoshihiro Amano, Motoko Tachihara, Takuji Suzuki, Junko Tanizaki, Shunichi Sugawara, Yoshitaka Zenke, Yukina Shirai, Takuo Hayashi, Keita Mori, Kazuhisa Takahashi","doi":"10.1016/s1470-2045(25)00001-4","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00001-4","url":null,"abstract":"<h3>Background</h3>Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains a standard treatment for chemotherapy-naive advanced or recurrent thymic carcinoma. We evaluated the activity and safety of atezolizumab combined with chemotherapy.<h3>Methods</h3>In this multicentre, single-arm, phase 2 trial in 15 hospitals in Japan, patients with metastatic or recurrent thymic carcinoma were treated with atezolizumab plus carboplatin and paclitaxel. Eligible patients were aged 20 years or older with histologically confirmed Masaoka stage III, IVA, or IVB thymic carcinoma not amenable for definitive treatment or recurrent thymic carcinoma after definitive treatment; and no previous history of systemic drug therapy for thymic carcinoma. The data of sex and race were defined via self-report. Patients received atezolizumab 1200 mg, carboplatin area under the curve 6 mg/mL per min, and paclitaxel 200 mg/m<sup>2</sup> intravenously every 3 weeks for up to six cycles, followed by atezolizumab 1200 mg intravenously every 3 weeks for up to 2 years until progression or unacceptable toxicity. The primary endpoint was objective response rate, based on an independent central review. The primary endpoint and safety were assessed in the per-protocol set. This trial was registered at Japan Registry of Clinical Trials, jRCT2031220144, and is closed to enrolment.<h3>Findings</h3>Between June 14, 2022, and July 6, 2023, 48 patients were enrolled and included in the efficacy and safety analyses. Median follow-up was 15·3 months (IQR 13·8–16·6). 29 (60%) patients were male and 19 (40%) of 48 patients were female. Median age of patients was 67·5 years (IQR 56·5–72·5). All patients were Asian. The objective response rate was 56% (95% CI 41–71; Fisher's exact test p<0·0001); 27 (56%) of 48 participants had a partial response. The most common adverse reactions of grade 3 or worse were neutropenia (27 [56%] of 48 patients), leukopenia (16 [33%]), febrile neutropenia (11 [23%]), and maculopapular rash (six [13%]). There were no treatment-related deaths and eight deaths overall.<h3>Interpretation</h3>In previously untreated advanced thymic carcinoma, the addition of atezolizumab to carboplatin and paclitaxel conferred clinically meaningful antitumour activity with a manageable safety profile. Thus, atezolizumab plus carboplatin and paclitaxel might become a viable treatment option for previously untreated advanced or recurrent thymic carcinoma.<h3>Funding</h3>Chugai Pharmaceutical.<h3>Translations</h3>For the Japanese translation of the abstract see Supplementary Materials section.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial

The Lancet Oncology

Pub Date : 2025-03-03 DOI: 10.1016/s1470-2045(24)00757-5

Nicholas Zdenkowski, Marion J J Kuper-Hommel, Samuel M Niman, Prudence A Francis, Sally Baron-Hay, William Fox, Alexander M Menzies, Rebecca Angus, Kevin Punie, Sarah Zardawi, Meredith M Regan, Sherene Loi

<h3>Background</h3>The optimal scheduling of PD-1 inhibitors with neoadjuvant chemotherapy in patients with early triple-negative breast cancer is unknown. We aimed to investigate the activity of two differing schedules of neoadjuvant nivolumab initiation with 12 weeks of carboplatin and paclitaxel for this patient population.<h3>Methods</h3>Neo-N is an investigator-initiated, non-comparative, open-label, randomised, phase 2 trial conducted at 12 hospitals in Australia, one in New Zealand, and one in Italy. Participants had to be aged 18 years or older; have an Eastern Cooperative Oncology Group performance status of 0–1, clinical stage I (cT1cN0) or II (cT1cN1, cT2cN0–1, or cT3cN0), oestrogen receptor expression of less than 1%, and progesterone receptor expression of less than 10%; had to be HER2 negative; and have previously untreated operable breast cancer with adequate organ function. Participants were stratified according to age and randomly assigned (1:1) centrally using a computer-generated sequence with a minimisation algorithm to either nivolumab 240 mg then 2 weeks later nivolumab 360 mg and carboplatin AUC5 every 3 weeks with concurrent paclitaxel 80 mg/m<sup>2</sup> once per week for 12 weeks (lead-in group) or concurrent nivolumab 360 mg and carboplatin AUC5 every 3 weeks with once per week paclitaxel 80 mg/m<sup>2</sup> for 12 weeks then 240 mg nivolumab 2 weeks later (concurrent group). Data were collected from registration until the 100-day safety follow-up visit, and survival follow-up continues. The primary endpoint was pathological complete response (ypT0/Tis ypN0) at the time of surgery, analysed in each group separately and in all patients who received at least one dose of all three study treatment (modified intention-to-treat population). The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12619001308189, and EudraCT, 2019-003465-18, and is ongoing.<h3>Findings</h3>Between July 6, 2020, and April 1, 2022, 124 participants were enrolled and 14 were ineligible. 110 participants were randomly assigned and 108 were included in the modified intention-to treat analysis (53 in the lead-in group and 55 in the concurrent group). Median follow-up was 12 months (IQR 7–18). All patients were female with a median age of 49 years (IQR 43–60). 18 (17%) patients had clinically node-positive disease; 37 (34%) had clinical stage I, 70 (65%) had stage II, and one (1%) had stage III disease. The pathological complete response rate was observed in 27 (51% [39–63]) of 53 patients in the nivolumab lead-in group and in 30 (55% [43–66]) of 55 in the concurrent group. Treatment-related grade 3–4 adverse events occurred in 70 (65%; 32 [60%] of 53 in the lead-in group and 38 [69%] of 55 in the concurrent group) of 108 patients, with the most common being decreased neutrophil count (25 [47%] of 53 in the lead-in group <em>vs</em> 28 [53%] of 55 in the concurrent group), anaemia (six [11%] <em>vs</em> ten [19%]), and i

{"title":"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial","authors":"Nicholas Zdenkowski, Marion J J Kuper-Hommel, Samuel M Niman, Prudence A Francis, Sally Baron-Hay, William Fox, Alexander M Menzies, Rebecca Angus, Kevin Punie, Sarah Zardawi, Meredith M Regan, Sherene Loi","doi":"10.1016/s1470-2045(24)00757-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(24)00757-5","url":null,"abstract":"<h3>Background</h3>The optimal scheduling of PD-1 inhibitors with neoadjuvant chemotherapy in patients with early triple-negative breast cancer is unknown. We aimed to investigate the activity of two differing schedules of neoadjuvant nivolumab initiation with 12 weeks of carboplatin and paclitaxel for this patient population.<h3>Methods</h3>Neo-N is an investigator-initiated, non-comparative, open-label, randomised, phase 2 trial conducted at 12 hospitals in Australia, one in New Zealand, and one in Italy. Participants had to be aged 18 years or older; have an Eastern Cooperative Oncology Group performance status of 0–1, clinical stage I (cT1cN0) or II (cT1cN1, cT2cN0–1, or cT3cN0), oestrogen receptor expression of less than 1%, and progesterone receptor expression of less than 10%; had to be HER2 negative; and have previously untreated operable breast cancer with adequate organ function. Participants were stratified according to age and randomly assigned (1:1) centrally using a computer-generated sequence with a minimisation algorithm to either nivolumab 240 mg then 2 weeks later nivolumab 360 mg and carboplatin AUC5 every 3 weeks with concurrent paclitaxel 80 mg/m<sup>2</sup> once per week for 12 weeks (lead-in group) or concurrent nivolumab 360 mg and carboplatin AUC5 every 3 weeks with once per week paclitaxel 80 mg/m<sup>2</sup> for 12 weeks then 240 mg nivolumab 2 weeks later (concurrent group). Data were collected from registration until the 100-day safety follow-up visit, and survival follow-up continues. The primary endpoint was pathological complete response (ypT0/Tis ypN0) at the time of surgery, analysed in each group separately and in all patients who received at least one dose of all three study treatment (modified intention-to-treat population). The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12619001308189, and EudraCT, 2019-003465-18, and is ongoing.<h3>Findings</h3>Between July 6, 2020, and April 1, 2022, 124 participants were enrolled and 14 were ineligible. 110 participants were randomly assigned and 108 were included in the modified intention-to treat analysis (53 in the lead-in group and 55 in the concurrent group). Median follow-up was 12 months (IQR 7–18). All patients were female with a median age of 49 years (IQR 43–60). 18 (17%) patients had clinically node-positive disease; 37 (34%) had clinical stage I, 70 (65%) had stage II, and one (1%) had stage III disease. The pathological complete response rate was observed in 27 (51% [39–63]) of 53 patients in the nivolumab lead-in group and in 30 (55% [43–66]) of 55 in the concurrent group. Treatment-related grade 3–4 adverse events occurred in 70 (65%; 32 [60%] of 53 in the lead-in group and 38 [69%] of 55 in the concurrent group) of 108 patients, with the most common being decreased neutrophil count (25 [47%] of 53 in the lead-in group <em>vs</em> 28 [53%] of 55 in the concurrent group), anaemia (six [11%] <em>vs</em> ten [19%]), and i","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

The Lancet Oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀